Cumberland Pharmaceuticals’ Ifetroban Improves Heart Function in Phase 2 DMD Trial

• Cumberland Pharmaceuticals announced October 26, 2026, plans to seek FDA approval for ifetroban to treat cardiomyopathy associated with Duchenne muscular dystrophy.
• The 12-month Phase 2 trial showed a 5.4% absolute improvement in left ventricular ejection fraction (p=0.002) versus combined placebo and matched natural-history controls.
• FDA questioned whether the proposed evidence would establish efficacy, requested additional analyses and suggested a randomized, placebo-controlled Phase 3 trial.
• The agency granted rolling review, allowing submission of completed application sections before the full filing.
• Ifetroban was generally well tolerated through 36 months, with no treatment-related serious adverse events or new safety concerns.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cumberland Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001087294-26-000072), on October 26, 2026, and is solely responsible for the information contained therein.